Collegium Pharmaceutical, INC Schedule 13G passive stakes

Fuller & Thaler Asset Management, Inc. has disclosed a beneficial ownership of 5.03% in Collegium Pharmaceutical, Inc. common stock as of June 30, 2026.

Principal Global Investors has reported a 5% beneficial ownership of Collegium Pharmaceutical's common stock as of June 30, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.01% of Collegium Pharmaceutical Inc.'s common stock as of June 30, 2026.

Janus Henderson Group plc has reported beneficial ownership of 5.8% of Collegium Pharmaceutical, Inc. common stock as of March 31, 2026.

Eventide Asset Management, LLC, along with Finny Kuruvilla and Robin C. John, has filed a Schedule 13G, reporting beneficial ownership of 4.5% of Collegium Pharmaceutical, Inc. common stock as of March 31, 2026.

Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have reported a beneficial ownership of 4.53% in Collegium Pharmaceutical, Inc.

Millennium Management and affiliated entities have disclosed a reduction in their beneficial ownership of Collegium Pharmaceutical, Inc. to below the 5% reporting threshold.

Invesco Ltd. has filed a Schedule 13G reporting a 5.0% beneficial ownership stake in Collegium Pharmaceutical Inc.

The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in Collegium Pharmaceutical Inc. due to an internal corporate realignment.

Rubric Capital Management LP and David Rosen reported a 4.73% beneficial ownership stake in Collegium Pharmaceutical, Inc. as of December 31, 2025.

Eventide Asset Management, along with Finny Kuruvilla and Robin C. John, reported a 5.9% beneficial ownership stake in Collegium Pharmaceuticals, Inc. as of December 31, 2025.

Renaissance Technologies LLC and its parent company have reported a 5.06% beneficial ownership stake in Collegium Pharmaceutical, Inc.

Renaissance Technologies LLC and its parent company have disclosed a 4.82% beneficial ownership stake in Collegium Pharmaceutical, Inc.

Principal Global Investors has updated its beneficial ownership in Collegium Pharmaceutical, Inc., reporting a 4.6% stake as of June 30, 2025.

Invesco Ltd. has disclosed a 4.9% beneficial ownership stake in Collegium Pharmaceutical Inc. as a passive investor.

Rubric Capital Management LP and its Managing Member, David Rosen, have disclosed a beneficial ownership of 9.34% in Collegium Pharmaceutical, Inc., holding 3,000,000 shares of common stock.

Pacer US Small Cap Cash Cows ETF, Pacer US Small Cap Cash Cows Growth Leaders ETF, Pacer Advisors, Inc., and Joe M. Thomson have jointly filed an amended Schedule 13G, reporting a combined beneficial ownership of 1.06% in Collegium Pharmaceutical, Inc. as of March 31, 2025.

Pacer US Small Cap Cash Cows ETF, Pacer US Small Cap Cash Cows Growth Leaders ETF, Pacer Advisors, Inc., and Joe M. Thomson collectively reported a 5.4% beneficial ownership stake in Collegium Pharmaceutical, Inc. as of December 31, 2024, held for passive investment purposes.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 15.6% in Collegium Pharmaceutical, Inc. as of March 31, 2025.

Rubric Capital Management LP and David Rosen have jointly disclosed a beneficial ownership of 7.29% in Collegium Pharmaceutical, Inc., totaling 2,350,000 shares of common stock as of December 31, 2024.

Invesco Ltd. has reported a 5.5% beneficial ownership stake in Collegium Pharmaceutical Inc., primarily for investment purposes.